JNJ - Johnson & Johnson
144.25 0.00 (0.00%)
After hours: 4:39PM EST
| Previous Close | 144.68 |
| Open | 145.02 |
| Bid | 143.50 x 800 |
| Ask | 144.50 x 1300 |
| Day's Range | 143.56 - 145.31 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 6,421,983 |
| Avg. Volume | 6,574,747 |
| Market Cap | 386.876B |
| Beta (3Y Monthly) | 0.31 |
| PE Ratio (TTM) | 253.51 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.60 (2.47%) |
| Ex-Dividend Date | 2018-11-26 |
| 1y Target Est | N/A |
- PR Newswire•2 days ago
Johnson & Johnson to Participate in the Citi's 2018 Global Healthcare Conference
NEW BRUNSWICK, N.J. , Nov. 12, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2018 Global Healthcare Conference on Wednesday, December 5 th , at the Lotte New York Palace ...
- PR Newswire•3 days ago
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition SINGAPORE , Nov. 12, 2018 /PRNewswire/ -- The Singapore National Eye Centre (SNEC), the ...
- PR Newswire•3 days ago
Singapore National Eye Centre, Singapore Eye Research Institute And Johnson & Johnson Vision Set Sights On Halting Global Myopia Epidemic
The first-of-its-kind public-private strategic partnership in Asia focused on myopia will create a deeper understanding of how the condition develops, how it progresses and how it may be intercepted. It will focus on developing predictive tools to identify those who may be at risk to develop high myopia, conduct research on the underlying mechanisms of myopia, progress novel therapies, and discover and validate methods to prevent the onset and progression of the condition.
- CNW Group•7 days ago
Johnson & Johnson Vision Announces Health Canada has issued a Medical Device License for First-of-its-Kind Contact Lens ACUVUE OASYS with Transitions Light Intelligent Technology
Johnson & Johnson Vision Announces Health Canada has issued a Medical Device License for First-of-its-Kind Contact Lens ACUVUE OASYS with Transitions Light Intelligent Technology
- PR Newswire•8 days ago
Johnson & Johnson to Participate in the Credit Suisse 27th Annual Healthcare Conference
NEW BRUNSWICK, N.J. , Nov. 6, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13 th , at The Phoenician in ...
- PR Newswire•8 days ago
Two Studies Measure Performance of ACUVUE OASYS with Transitions Light Intelligent Technology Contact Lenses in Simulated Sunlight, Day and Night Driving Conditions
- First-of-its-kind photochromic contact lens delivered improved visual function compared to transparent contact lenses in simulated sunlight - Subjects wearing photochromic contact lenses performed equal ...
- PR Newswire•19 days ago
Court Issues Ruling in ZYTIGA® Patent Infringement Litigation
NEW BRUNSWICK, N.J., Oct. 26, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that the United States District Court, District of New Jersey has issued a ruling invalidating all asserted claims of U.S. Patent No. 8,822,438 for ZYTIGA® (abiraterone acetate). The Court held that the patent claims would be infringed if the patent were valid. The patent infringement case was filed against several companies who have submitted Abbreviated New Drug Applications for 250 mg and/or 500 mg tablets.
- PR Newswire•23 days ago
Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.
NEW BRUNSWICK, New Jersey, Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (4924.T) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the "tender offer") to acquire all of the outstanding shares of the Company not already held by Johnson & Johnson and its affiliates for ¥5,900 per share, which equates to approximately ¥230 billion. The acquisition will include the Company's range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products. The Company's skincare portfolio is expected to strengthen Johnson & Johnson's market presence in Japan with key customers, and more broadly bolster its offering in science-based, efficacious dermocosmetic brands.
- PR Newswire•23 days ago
Johnson & Johnson Announces Offer to Acquire Ci:z Holdings Co., Ltd.
NEW BRUNSWICK, N.J., Oct. 23, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that they have agreed with Ci:z Holdings Co., Ltd. (4924.T) (the "Company"), a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products, to launch an all-cash offer (the "tender offer") to acquire all of the outstanding shares of the Company not already held by Johnson & Johnson and its affiliates for ¥5,900 per share, which equates to approximately ¥230 billion. The acquisition will include the Company's range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skincare products. The Company's skincare portfolio is expected to strengthen Johnson & Johnson's market presence in Japan with key customers, and more broadly bolster its offering in science-based, efficacious dermocosmetic brands.
- GlobeNewswire•23 days ago
Detailed Research: Economic Perspectives on DexCom, MiX Telematics, Resolute Forest Products, Equinix, Johnson & Johnson, and Vedanta — What Drives Growth in Today's Competitive Landscape
NEW YORK, Oct. 22, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•27 days ago
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2018
NEW BRUNSWICK, N.J., Oct. 18, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2018 of $0.90 per share on the company's common stock. The dividend is payable on December 11, 2018 to shareholders of record at the close of business on November 27, 2018. At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress.
- ACCESSWIRE•28 days ago
Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...
- PR Newswire•29 days ago
Johnson & Johnson Reports 2018 Third-Quarter Results:
2018 Third-Quarter Sales of $20.3 Billion Increased 3.6% versus 2017 2018 Third-Quarter EPS was $1.44 2018 Adjusted Third-Quarter EPS of $2.05 increased 7.9%* Strong Operational Sales and Adjusted EPS ...
- ACCESSWIRE•29 days ago
Johnson & Johnson to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Johnson & Johnson (NYSE: JNJ ) will be discussing their earnings results in their 2018 Third Quarter Earnings to be held on October 16, 2018 at 8:30 AM Eastern ...
- GlobeNewswire•last month
Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board
Eric A. Rose, M.D., biotech and medical device business leader as well as world-renowned cardiac surgeon and scientist who performed the landmark achievement of the first.
- PR Newswire•last month
Johnson & Johnson Vision Launches Worldwide Campaign to #SpotlightSight in Honor of World Sight Day
Nearly 285 million people around the world face impaired vision, and 80 percent of those cases are preventable with early diagnosis and treatment.1 That's why Johnson & Johnson Vision, a broad-based global leader in eye health, has launched a worldwide campaign to #spotlightsight in honor of World Sight Day on October 11.
- GlobeNewswire•last month
Platinum Equity Completes $2.1 Billion Acquisition of LifeScan From Johnson & Johnson
Platinum Equity today announced that its acquisition of LifeScan from Johnson & Johnson (JNJ) for approximately $2.1 billion has been completed, with the exception of certain non-U.S. jurisdictions that are each expected to close at a later date, subject to individual country regulatory requirements. LifeScan is a leader in blood glucose monitoring products with 2017 net revenue of approximately $1.5 billion. “LifeScan is an innovative company that has been a leader in diabetes care for more than 30 years,” said Platinum Equity Partner Jacob Kotzubei.
- PR Newswire•last month
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
NEW BRUNSWICK, New Jersey, Oct. 2, 2018 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 billion. LifeScan, Inc. is a world leader in blood glucose monitoring and maker of the OneTouch® brand of products. The Johnson & Johnson Family of Companies will continue to serve those impacted by diabetes through innovative products, services and solutions from its Medical Device, Pharmaceuticals and Consumer businesses.
- PR Newswire•last month
Johnson & Johnson Completes Divestiture of LifeScan to Platinum Equity
NEW BRUNSWICK, N.J. , Oct. 2, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that it has completed the divestiture of its LifeScan business to Platinum Equity for approximately $2.1 ...
- PR Newswire•last month
Where will the next big idea in healthcare come from? Johnson & Johnson is counting on nurses.
NEW BRUNSWICK, N.J., Oct. 1, 2018 /PRNewswire/ -- There's a reason the saying goes, "nurse someone back to health." Throughout history, nurses have been important facilitators of health – caring for the sick when others would not, identifying smarter and better ways to heal and developing life-saving methods. Today, Johnson & Johnson (JNJ) is launching a new campaign that does more than just recognize nurses as critical partners on the front lines of health care – it empowers them as innovators. Through the "Nurses Innovate QuickFire Challenge," Johnson & Johnson is inviting the more than 3.2 million nurses1 in the United States to submit ideas for new devices, health technologies, protocols or treatment approaches.
- PR Newswire•2 months ago
Janssen Announces Results of Esketamine Nasal Spray Phase 3 Study in Patients with Treatment-Resistant Depression
Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression TITUSVILLE, N.J. , Sept. 21, 2018 /PRNewswire/ -- The ...
- PR Newswire•2 months ago
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
- PR Newswire•3 months ago
UPDATE: Johnson & Johnson to Host Investor Conference Call on the Pharmaceutical Business
Mathai Mammen, Global Head, Janssen Research & Development and Lesley Fishman, Senior Director Investor Relations will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
- PR Newswire•3 months ago
Johnson & Johnson to Participate in the 2018 Morgan Stanley 16th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J. , Aug. 27, 2018 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2018 Morgan Stanley 16 th Annual Global Healthcare Conference on Friday, September 14 th , at The ...
- PR Newswire•3 months ago
Johnson & Johnson to Host Investor Conference Call on the Phase 3 MARINER and COMMANDER HF Studies for XARELTO®
Vanessa Broadhurst, President, Cardiovascular & Metabolism, Janssen Pharmaceuticals Inc. and Christopher DelOrefice, Vice President, Investor Relations will host the call. The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.